Breast cancer circulating biomarkers: advantages, drawbacks, and new insightsDaniele Generali, Chiara Senti, Paola Brambilla et al.|Tumor Biology|2015Cited by 47
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancerGiacomo Bregni, Francesco Sclafani, Caroline Vandeputte et al.|Acta Oncologica|2021Cited by 11
A Phase II Study of Olaparib in Breast Cancer Patients: Biological Evaluation from a ‘Window of Opportunity’ TrialGiandomenico Roviello, Daniele Generali, Manuela Milani et al.|Future Oncology|2016Cited by 10
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast CancersGiandomenico Roviello, Daniele Generali, Manuela Milani et al.|Clinical Breast Cancer|2016Cited by 7